



Special Issue Reprint

Immunotherapies for Acute Myeloid Leukemia

www.mdpi.com/books/reprint/2516

Edited by Jochen Greiner

ISBN 978-3-03936-110-6 (Hardback) ISBN 978-3-03936-111-3 (PDF)



The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. Consequently, T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs), or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different solid tumor types as well as in hematological malignancies. T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusions (DLI) due to the graft-versus-leukemia effect. In acute myeloid leukemia (AML) after intensive chemotherapy, most patients achieve complete remission; however, the overall survival for all AML patients, especially in elderly patients, is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and improve overall survival. This Special Issue will focus on immunotherapeutic approaches in AML in established therapies, like the allogeneic stem cell transplantation including new concepts improving the graft-versus-leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition, bi-specific antibodies, and CAR-T-cell approaches.



Order Your Print Copy You can order print copies at www.mdpi.com/books/reprint/2516

MDPINBOOKS Publishing Open Access Books & Series

MDPI Books offers quality open access book publishing to promote the exchange of ideas and knowledge in a globalized world. MDPI Books encompasses all the benefits of open access – high availability and visibility, as well as wide and rapid dissemination. With MDPI Books, you can complement the digital version of your work with a high quality printed counterpart.



Open Access

Your scholarly work is accessible worldwide without any restrictions. All authors retain the copyright for their work distributed under the terms of the Creative Commons Attribution License.



Author Focus

Authors and editors profit from MDPI's over two decades of experience in open access publishing, our customized personal support throughout the entire publication process, and competitive processing charges as well as unique contributor discounts on book purchases.



High Quality & Rapid Publication

MDPI ensures a thorough review for all published items and provides a fast publication procedure. State-of-the-art research and time-sensitive topics are released with a minimum amount of delay.



ᆔ

High Visibility

Due to our global network and well-known channel partners, we ensure maximum visibility and broad dissemination. Title information of books is sent to international indexing databases and archives, such as the Directory of Open Access Books (DOAB), and the Verzeichnis Lieferbarer Bücher (VLB).

Print on Demand and Multiple Formats

MDPI Books are available for purchase and to read online at any time. Our print-on-demand service offers a sustainable, cost-effective and fast way to publish MDPI Books printed versions.

MDPI AG Grosspeteranlage 5 4052 Basel Switzerland Tel: +41 61 683 77 34 www.mdpi.com/books books@mdpi.com

